What:Relypsa (NASDAQ: RLYP) , a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica ...

As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP ...

So what: The terms of this deal received a mixed reception among Relypsa's shareholder base. The apparent reason for the discontent is that the Street's high-end price target (before this deal was ...

SOURCE: FLICKR USER STEVE JURVETSON. What:Swirling rumors that an acquirer might step up to buy the company caused shares inRelypsa, to soar 67.6% higher today. So what: The company has been the ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million.

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

What: Shares of Relypsa (RLYP +0.00%) exploded more than 30% higher as of 3:30 p.m. today after a rumor broke that Merck (MRK +3.13%) has plans to make an offer to buy out the company. So what: ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Relypsa Inc. (NASDAQ: RLYP) rose early in Monday’s ...

The U.S. Food and Drug Administration approved Relypsa Inc's drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is ...

What: After a key competitor was acquired last Friday, shares in Relypsa climbed by 10% earlier today. So what: AstraZeneca reported on Friday that it is acquiring ZS Pharma for $2.7 billion to get ...